General contact

Main switchboard

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST


Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999


Investor Relations

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content


Novartis was the first pharmaceutical company with a global leadership position in both patented prescription and generic pharmaceuticals.

Sandoz plays a critical role in the Novartis strategy of offering a complete range of treatment options to patients, physicians and healthcare providers worldwide. This broad portfolio helps to make affordable, high-quality medicines available to patients world-wide and helps stabilize healthcare systems around the world as governments face increasing cost containment pressures.

Two main elements empower the Sandoz business strategy:

  • Global reach and reputation: In addition to its unique position within Novartis, Sandoz benefits from a strong global presence and powerful brand recognition worldwide.
  • Unique expertise: Sandoz distinguishes itself primarily through its ability to develop, produce and commercialize differentiated medicines. Sandoz is the pioneer and global leader of biosimilars — follow-on versions of biopharmaceuticals following loss of patent protection — with the first three approved and marketed products in the EU (human growth hormone Omnitrope, anemia medicine Binocrit, and oncology medicine Zarzio).

Sandoz - adding value through key differentiated pillars

Sandoz differentiates itself through its ability to develop, produce and commercialize complex, value-added products. The company specializes in complex, differentiated products with a focus on biosimilars, as well as generic injectables, inhalables, ophthalmics, dermatology medicines, anti-infectives and other difficult-to-make generics.

For additional information please roll-over the Sandoz graphic below.


High-quality, clinically-proven alternatives to existing biologics that offer comparable safety and efficacy at a more affordable price. Sandoz pioneered and is the clear #1 in the combined regions of North America, Europe, Japan and Australia, with each of its three marketed biosimilars the leading biosimilar in their respective markets.